Disposable Circumcision Ring — Adult & Pediatric

Swiss importers link their CHRN to devices someone else has registered; they never register products. What must exist before linking, who pays which fee, and how 31 December 2026 and 1 April 2027 split between supplier and importer.

Only a manufacturer's Article 10a notice triggers the legal relay. How EU importers, distributors and procedure-pack producers tell it apart from a backorder, whom they must forward it to, and what contracts should add.

If the first EU unit of a UDI-DI was placed before 28 May 2026, Regulation (EU) 2024/1860 gives the manufacturer 12 months from the functionality notice to enter the device record. The Commission graphic prints 28 November 2026. A first unit placed on or after 28 May 2026 needs the record first.

When a supplier says an NMPA class adjustment changed the certificate on file, which document a buyer may still cite, and when a shipment has to stop.

Which Indian authorization a sterile single-use device actually needs, who can hold it, what the Second Schedule charges, and which foreign approvals skip a clinical investigation.

An operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Brazilian market under RDC 751/2022, RDC 848/2024, the 14 August 2026 Código Único transition, 4-year MDSAP CBPF validity, IN 290/2024 AREE reliance, and the 2026 SIUD UDI database.

A procurement check for distributors and tender officers who need to know whether a circumcision-device quotation matches the WHO list, the public assessment report, and the 25 September 2026 framework move.

A five-step receiving inspection protocol for distributor QA leads and hospital procurement engineers navigating ISO 2859-1:2026, destructive sample budgets, defect-class AQLs, and lot CoA reliance.

A threshold, composition, and tender-file verification guide for EU distributors, wholesalers, and hospital procurement leads navigating Commission Implementing Regulation (EU) 2025/1197 and the autumn 2026 review clock.

A line-level duty-stack and verification guide for US importers, distributors, and procurement leads navigating the 24 July 2026 forced-labor tariff, de minimis suspension, and Q4 trade clocks.

NMPA published Notice 14 on 15 September 2026; its 200 graded items apply from 1 November 2026. Until then, CFDA 2015 No. 218 remains the on-site inspection file.

Match a circumcision stapler CoA to China's official stapler-standard scope: YY 0875-2023 covers linear staplers and cartridges, not circular prepuce cutters.

An incoming audit guide for medical device distributors, OEMs, and private-label partners: why 21 CFR 820.30 is reserved under QMSR, how ISO 13485:2016 Clause 7.3 carries the legal duties, what CP 7382.850 inspects under Design and Development, how EN ISO 13485 and GB/T 42061-2022 overlay the file, the DHF-to-medical-device-file pivot, and an 8-point buyer acceptance protocol.

An incoming-inspection and supplier-qualification guide for international medical-device distributors, hospital procurement teams, and OEM buyers evaluating Chinese ethylene oxide sterilization certificates, GB 18279 edition shifts, and FDA or EU cycle-file overlays in September 2026.

An incoming-inspection and supplier-qualification guide for international medical-device distributors, hospital buyers, and OEM engineers navigating ethylene-oxide cycle certificates, product adoption, single-batch release, and commercial pallet density across the US FDA, ISO, and AAMI frameworks in September 2026.

An operational procurement and regulatory guide for international medical-device distributors, hospital buyers, and OEM sellers navigating remaining-shelf-life tender clauses, incoming-inspection dock tests, and labelled expiration dates across the US, EU, UNICEF, and WHO frameworks in September 2026.

An operational technical and regulatory guide for international medical-device distributors, OEM buyers, and quality engineers evaluating sterile-barrier packaging validation files, declarations of conformity, and recognition timelines across the US, EU, and China in September 2026.

An operational technical and regulatory guide for international medical-device distributors, OEM buyers, and quality engineers evaluating EO-sterilized single-use device residual certificates of analysis, dissipation curves, and regulatory recognition across the US, EU, and China in 2026.

An operational factory-qualification and supplier-audit guide for international distributors, private-label/OEM buyers and hospital procurement teams evaluating Chinese sterile medical-device manufacturers under NMPA Announcement No. 107 of 2025, the 132-article Good Manufacturing Practice effective 1 November 2026, and the simultaneous repeal of CFDA Announcement No. 64 of 2014.

An operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Mexican market under Ley General de Salud Articles 262 and 376, RIS Article 83 risk classes, the 2010 FDA/Canada and 2012 Japan equivalence agreements, and the 18 July 2025 Option F abbreviated pathway.

An operational technical and regulatory guide for international medical-device distributors, OEM buyers, and quality teams evaluating CE-marked sterile single-use devices under ISO 15223-1 clause 5.1.2, EU MDR/IVDR harmonised-standard withdrawal dates, and US FDA consensus-recognition clocks.

An operational regulatory guide for international medical device distributors, OEM buyers, and foreign manufacturers placing sterile single-use devices on the Japanese market under PMD Act Articles 23-2, 23-2-4, and 23-2-17, MHLW Ordinance 169, and official PMDA user-fee schedules.

A field-by-field file-review guide for medical device distributors, OEM buyers, and hospital procurement teams evaluating sterile single-use suppliers after 2 February 2026: why 21 CFR 820.70, 820.75, and 820.80 are reserved, what ISO 13485 Clause 7.5 and 21 CFR 820.45 mandate for production, process validation, and labeling inspection, and how FDA Compliance Program 7382.850 audits Production and Service Provision.

An operational regulatory guide for international medical device distributors, OEM buyers and manufacturers placing sterile single-use devices on the Republic of Korea market under the Medical Devices Act, Enforcement Rule Article 65 fees, and Act No. 21263 QMS conformity rules.

An incoming audit guide for medical device distributors, OEMs, and hospital procurement teams: why 21 CFR 820.100 and 820.198 are reserved under QMSR, how ISO 13485 Clauses 8.2.2, 8.3, 8.5.2, and 8.5.3 carry the legal duties, what 21 CFR 820.35 adds on top, what CP 7382.850 inspects under Measurement, Analysis, and Improvement, why an MDR report is not the complaint file, and a 7-point buyer acceptance protocol.

A definitive, decision-led guide for international manufacturers and Singapore distributors: navigating Singapore Health Sciences Authority (HSA) medical device registration, SMDR listings, Class A SHARE notifications, Registrant mandates, dealer licences, GN-15 R13 evaluation pathways, and 2026 fee cards.

A register-first supplier map that separates brands, legal manufacturers, sterilizers, listing establishments, certificate holders and distributors before an RFQ is issued.

A practical buyer's audit guide for medical device purchasing and outsourcing files: why 21 CFR 820.50 is reserved under QMSR, how ISO 13485 Clauses 4.1.5 and 7.4 carry the legal duties, what FDA Compliance Program 7382.850 inspects, why supplier-audit reports are no longer exempt, and a 7-point incoming acceptance checklist.

An operational decision guide for international medical-device distributors, private-label/OEM buyers, and overseas manufacturers: navigating Health Canada Medical Device Licences (MDL) under SOR/98-282 s 26, Medical Device Establishment Licences (MDEL) under GUI-0016 Table 1, the mandatory MDSAP quality filing condition, Schedule 1 risk classification, official 1 April 2026 fees including the private-label MDL, MDALL versus MDEL listing verification boundaries, and the SOR/2026-110 modernization coming-into-force timeline.

An operational decision guide for international distributors, private-label/OEM buyers, and overseas manufacturers: navigating Australian Register of Therapeutic Goods (ARTG) inclusion under the Therapeutic Goods Act 1989, the Australian sponsor mandate, Manufacturer Evidence pre-approval, TGA risk classification (Classes I, IIa, IIb, III), Comparable Overseas Regulator (COR) pathways, July 2026 fee schedules, and the class-phased 1 July 2026 Unique Device Identification (AusUDID) rollout.

A practical buyer's audit guide for medical device risk management files: separating ISO 13485 QMSR process mandates from ISO 14971 conformity, verifying EN ISO 14971:2019+A11:2021 for EU MDR, navigating China's GB/T 42062-2022, and executing a 7-point incoming acceptance protocol.

An operational decision guide for international distributors, private-label/OEM buyers, and overseas manufacturers: navigating the Kingdom of Saudi Arabia's MDMA requirements under Law M/54, the Technical File Assessment route, SFDA Classes A–D (MDS-G008), the May 2025 fee schedule, the 3 May 2026 bundling criteria (MDS-G028), Authorized Representative mandates, importer establishment licensing, and port-clearance verification.

An operational decision guide for international distributors, OEM buyers, and non-UK manufacturers: navigating Great Britain's CE-recognition timelines (2028 vs 2030), UKCA requirements under UK MDR 2002, UK Responsible Person mandates, DORS registration and 2026 fees, Northern Ireland EUDAMED rules, and the in-force June 2025 post-market surveillance obligations.

A practical five-check verification workflow, Annex XII reading grid, NANDO designation guide, EUDAMED status decoder, and distribution-agreement schedule for international distributors qualifying European medical-device suppliers.

A multi-jurisdiction regulatory matrix and distributor evidence checklist comparing US 21 CFR 884.4530, EU MDR Class IIa Rule 6, China provincial Class II NMPA registrations, and WHO prequalification gates.

An original FDA surveillance analysis of 31 circumcision device 510(k) clearances, 34 recalls, and 942 MAUDE adverse-event reports (all-time; 592 in the 2015–2026 window) translated into tender acceptance criteria and supplier-vigilance questions for disposable circumcision stapler, ring, and clamp devices.

A component-level technical guide to the single-use circumcision anastomat and stapler: the bell-and-staple firing mechanism, what belongs in the sterile convenience kit, the staple-formation and sterile-barrier lot-acceptance tests, and the US, EU and China classification — including why no US 510(k) predicate and no WHO prequalification exist for the stapler.

A practical audit and qualification checklist for distributors and private-label buyers evaluating circumcision device manufacturers, distinguishing ISO 13485 from product-specific CE certificates, defining legal-manufacturer obligations, and protecting territory exclusivity.

A B2B procurement framework for turning ex-works device quotes into defensible landed-cost-per-unit figures, incorporating size-mix MOQ, sterile packaging, tariff treatment, customs classification, and lot-release terms.

Qualifying a radiation-sterilized single-use device OEM requires verifying an ISO 11137 validation protocol, substantiating the 25 kGy or 15 kGy sterilization dose via VDmax, selecting the optimal modality (gamma vs e-beam vs X-ray), capping polymer maximum doses, and aligning with the 4-month dose-audit interval under ISO 11137-1:2025 and the FDA Radiation Master File Pilot.

Matching device mechanics to clinical throughput, establishing adult and pediatric size ladders, and verifying FDA, CE, and NMPA registration evidence.

How single-use rings, circular staplers and disposable-suture kits turned a 20-minute scalpel-and-suture operation into a roughly 7-minute sutureless one — an Asia-led device shift the world adopted before the US FDA recorded it.